72
Participants
Start Date
February 28, 2009
Primary Completion Date
November 30, 2009
Study Completion Date
October 31, 2012
Ipilimumab
Solution, intravenous, 10mg/kg, every 3 weeks in the induction phase, up to 4 doses in the induction phase, 48 weeks
Carboplatin
Solution, intravenous, Area Under the Concentration Time Curve=6, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
Paclitaxel
Solution, intravenous, 175 mg/m2, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
Dacarbazine
Solution, intravenous, 850 mg/m2, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
Memorial Sloan Kettering Cancer Center, New York
Blumenthal Cancer Center, Carolinas Medical Center, Charlotte
H Lee Moffit Cancer Cnt And Res Inst, Tampa
The Angeles Clinic & Research Inst., Los Angeles
Lead Sponsor
Collaborators (1)
Medarex
INDUSTRY
Bristol-Myers Squibb
INDUSTRY